News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: December 5, 2024
A new report demonstrated why patients benefit most from starting on a two-drug chemotherapy regimen instead of a three-drug regimen.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: November 22, 2024
This approval makes the bispecific antibody the first HER2-targeted treatment to carry the indication.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: April 28, 2022
A fifth shot of an mRNA vaccine represents a second booster because the primary mRNA immunization series for immu...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: March 23, 2022
Two ctDNA tests used for this purpose are marketed in the United States.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: March 22, 2022
Approval is based on findings that show median progression-free survival of 10.1 months.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: March 16, 2022
Concerns over unnecessary prostatectomies took precedence over the benefits of screening for early high-risk disease.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: March 9, 2022
The mass resignation of an EAB, a panel of outside experts that help shepherd cancer centers through the NCI grant process, is “highly unusual.”
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: March 8, 2022
Although maintenance strategies have typically demonstrated a PFS benefit, that advantage may come at “the expense of ongoing ... toxicity.”
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: February 17, 2022
As cancer treatment becomes increasingly individualized, “sex may be an important consideration.”
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: February 16, 2022
“Patients who have delayed preventative care during the pandemic should be encouraged to resume treatment as soon as possible.”
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: February 8, 2022
“This may also mark the arrival of a new era in nuclear medicine where molecular imaging helps visualize and characterize the entire tumor burden i...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: January 3, 2022
Tepotinib for NSCLC, enfortumab vedotin for urothelial cancer and voxelotor for sickle cell disease are currently approved in the U.S.
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: December 20, 2021
Voxelotor for hemolytic anemia in sickle cell disease can now be used in children from 4...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: November 18, 2021
For the first time, new data show that risk for breast cancer&nb...
News
- Author:
- M. Alexander Otto, MMS, PA
Publish date: November 8, 2021
The overall risk of metastasis is between 6% and 22%, with younger women having a higher risk.
